OR WAIT null SECS
Data showed that the drug candidate activated T regulatory cells, believed to serve a crucial role in protecting the body from uncontrolled inflammation or autoimmunity.
Regen BioPharma, a biotechnology company based in La Mesa, CA, announced that it received positive data suggesting that its cannabidiol-based therapeutic (CBD) approach successfully reduced rheumatoid arthritis in animal models.
According to an Oct. 3, 2019 press release, data showed that the drug candidate activated T regulatory cells, which the company believes serve a crucial role in protecting the body from uncontrolled inflammation or autoimmunity.
"The reduction of rheumatoid arthritis disease, which correlated with an increase in T regulatory cell numbers and a decrease in Th17 cells induced by the cannabidiol-based therapeutic drug mimics natural conditions in which autoimmunity goes into remission," said Thomas Ichim, PhD, senior advisor to Regen, in the press release. “We believe that we may have uncovered a new approach to autoimmunity that spares the patients the toxicity and side effects of non-specific immune suppression, which is the current treatment paradigm today."
"These current findings add another therapeutic candidate to our existing portfolio which centers on modulation of inflammatory pathways such as NR2F6," added David Koos, chairman and CEO of Regen, in the press release. "What this means to our small-molecule drug development programs is CBD appears, when used with other compounds, to amplify the desired outcome. Our current pipeline of NR2F6 small molecules both augment and inhibit interleukin-17 production, we see potential synergy between today's disclosed data and our ongoing small molecule programs."
Source: Regen BioPharma